CAMBRIDGE, Mass.--(BUSINESS WIRE)--Rubius Therapeutics, a biotechnology company pioneering the creation of
a new class of extraordinarily active, ready-to-use and life-changing
cellular therapies, today announced the appointment of Andrew Oh as
Chief Financial Officer. Mr. Oh brings to Rubius more than 20 years of
experience in finance and the biopharmaceutical industry.

Prior to joining Rubius, Mr. Oh served as Chief Investment Officer and
Chief Operating Officer at Leerink Pharmaceutical Investments, a
subsidiary of Leerink Capital Partners. Prior to Leerink, Mr. Oh was a
senior analyst covering global pharmaceutical companies and was a
portfolio manager at Fidelity Investments for seven years. Mr. Oh
managed the Fidelity Select Pharmaceuticals Portfolio fund which was
rated by Lipper as the number one global health/biotechnology fund based
on three and five year performance. He received a B.A. in Biology from
Washington University in St. Louis and holds a MBA from Northwestern’s
Kellogg School of Management.

“Andrew’s career-long experience as an investor and analyst at some of
the best financial institutions, coupled with his extensive network in
the global biopharmaceutical community make him an excellent addition to
the Rubius team as the company continues to grow and work to advance the
next generation of cellular therapies,” said Torben Straight Nissen,
Ph.D., President of Rubius Therapeutics.

“Rubius is one of the most exciting biotech companies I have seen in my
investing career and has the potential to transform care for people
suffering from a broad range of serious diseases,” said Mr. Oh. “I am
honored to be part of a team dedicated to pioneering the next generation
of cellular therapies and the development of breakthrough therapies for
patients in need.”

About Rubius Therapeutics

Rubius Therapeutics, a 2017 “Fierce 15” award winner, is creating RCTs™
as a new class of medicines. Leading applications include programs in
cancer, enzyme deficiency diseases and the induction of tolerance to
treat autoimmune disease. The company was conceived and launched by
Flagship VentureLabs®, the innovation foundry where a team of scientific
entrepreneurs systematically evolve enterprising ideas based upon
previously undiscovered areas of science into real-world inventions and
ventures. Rubius® was founded by Flagship Pioneering in 2014. For more
information please visit www.rubiustx.com.

About RCT™ Products

RCT™ products are genetically engineered, enucleated red cells that are
being developed to provide allogeneic, ready-to-use cellular therapies
to patients across multiple therapeutic areas. The advantages of RCT
products over other therapies include immuno-privileged presentation of
proteins within or on the red cell, high target avidity and affinity,
and long circulation half-life. Rubius RCTs exhibit fundamentally unique
and potent biology; that have been engineered to replace missing enzymes
for patients living with a variety of rare diseases, to kill tumors, and
to upregulate or downregulate the immune system to treat both cancer and
autoimmune disorders.